Related articles

In the past, most people viewed cancer prevention as something to consider only after symptoms appeared. Unfortunately, by the time cancer is detected through conventional screening, it often has already progressed to a later stage, missing the best opportunity for early intervention. With the advancement of molecular biology and genetic technology, healthcare is entering a new era—one that emphasizes prediction and prevention. At the forefront of this change is Onco-D-clare.

With the continuous advancement of modern medicine and precision genetics, research increasingly shows that cancer is not caused by a single factor, but by a complex interaction between genes, environment, and lifestyle. Traditional standardized care often struggles to address these individual differences. Onconomics Plus was developed to bridge this gap — bringing truly personalized and precise care to people facing cancer.

In the past, many people regarded “prevention” as an abstract concept, often only paying attention to health when noticeable abnormalities appeared or when there was a family history of cancer. Today, with advances in modern medicine and molecular science, cancer prevention is no longer just a theoretical idea—it can be quantified and monitored, allowing individuals to actively manage their health.

With the rise of precision medicine and molecular biology, our understanding of cancer has evolved from focusing solely on treatment after diagnosis to emphasizing early detection and personalized prevention. Among these advancements, personalized testing such as RGCC is reshaping the way people view health management. It not only provides deeper insight into individual risks but also helps individuals take proactive steps to maintain long-term well-being.